Anemia During Sequential Induction Chemotherapy and Chemoradiation for Head and Neck Cancer: The Impact of Blood Transfusion on Treatment Outcome

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 2, 2009, Pages 391-398

  Bhide, Shreerang A ^a,b   Ahmed, Merina ^a,b   Rengarajan, Vijayan ^b   Powell, Ceri ^b   Miah, Aisha ^b   Newbold, Kate ^b   Nutting, Christopher M ^a,b   Harrington, Kevin J ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Anemia; Chemoradiation; Head and neck cancer; Sequential

Indexed keywords

CHEMOTHERAPY; COMPUTER OPERATING SYSTEMS; DISEASE CONTROL;

ANEMIA; BLOOD TRANSFUSIONS; CHEMORADIATION; COMPLEX INTERACTIONS; HEAD AND NECK CANCER; LOCOREGIONAL CONTROLS; OVERALL SURVIVALS; RADICAL TREATMENTS; RETROSPECTIVE REVIEWS; SEQUENTIAL; SEQUENTIAL TREATMENTS; SQUAMOUS CELL CANCER OF THE HEAD AND NECKS; TUMOR HYPOXIAS;

BLOOD;

CARBOPLATIN; CISPLATIN; FLUOROURACIL;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEMOGLOBIN DETERMINATION; HUMAN; HYPOPHARYNX TUMOR; INCIDENCE; LARYNX TUMOR; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH TUMOR; MUCOSAL TOXICITY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX TUMOR; NEPHROTOXICITY; NEUROTOXICITY; OROPHARYNX TUMOR; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARANASAL SINUS TUMOR; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HEMOGLOBIN A; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 58149329087     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.04.052     Document Type: Article

References (31)

1. Monnerat C., Faivre S., Temam S., et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 13 (2002) 995-1006
2. Lefebvre J.L., Chevalier D., Luboinski B., et al. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88 (1996) 890-899
3. Paccagnella A., Orlando A., Marchiori C., et al. Phase III trial of initial chemotherapy in Stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86 (1994) 265-272
4. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
5. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007) 1705-1715
6. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357 (2007) 1695-1704
7. Lefebvre J.L. Laryngeal preservation in head and neck cancer: Multidisciplinary approach. Lancet Oncol 7 (2006) 747-755
8. Psyrri A., Kwong M., DiStasio S., et al. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: Long-term follow-up. J Clin Oncol 22 (2004) 3061-3069
9. Urba S.G., Moon J., Giri P.G., et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: A Southwest Oncology Group Trial. J Clin Oncol 23 (2005) 88-95
10. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16 (1998) 1318-1324
11. Glaser C.M., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50 (2001) 705-715
12. Stadler P., Becker A., Feldmann H.J., et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 44 (1999) 749-754
13. Vokes E.E., Stenson K., Rosen F.R., et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 21 (2003) 320-326
14. Bhide S., Miah A., Barbachano Y., et al. Neo-adjuvant chemotherapy followed by radical chemo-radiation in treatment of advanced head and neck cancer. Eur J Cancer 5 suppl (2007) 329
15. Becker A., Stadler P., Lavey R.S., et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 46 (2000) 459-466
16. Grant D.G., Hussain A., and Hurman D. Pre-treatment anemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol 113 (1999) 829-833
17. Lee W.R., Berkey B., Marcial V., et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 42 (1998) 1069-1075
18. Rades D., Kuhn H., Schultze J., et al. Prognostic factors affecting locally recurrent rectal cancer and clinical significance of hemoglobin. Int J Radiat Oncol Biol Phys 70 (2008) 1087-1093
19. Machtay M., Pajak T.F., Suntharalingam M., et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: A randomised trial of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 69 (2007) 1008-1017
20. Varlotto J., and Stevenson M.A. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 63 (2005) 25-36
21. Nielsen H.J., Werther K., Mynster T., and Brunner N. Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion 39 (1999) 1078-1083
22. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
23. Patel H.B., Nasir F.A., Nash G.F., et al. Enhanced angiogenesis following allogeneic blood transfusion. Clin Lab Haematol 26 (2004) 129-135
24. Werther K., Christensen I.J., and Nielsen H.J. The association between preoperative concentration of soluble vascular endothelial growth factor, perioperative blood transfusion, and survival in patients with primary colorectal cancer. Eur J Surg 167 (2001) 287-292
25. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46 (1998) 135-146
26. Overgaard J., Hansen H.S., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362 (2003) 933-940
27. Kapp K.S., Poschauko J., Geyer E., et al. Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 54 (2002) 58-66
28. Santin A.D., Bellone S., Parrish R.S., et al. Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix. Gynecol Obstet Invest 56 (2003) 28-34
29. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
30. Overgaard J., Sand Hansen H., Specht L., et al. Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)-the Danish Head and Neck Cancer Group DAHANCA 10. Eur J Cancer 5 suppl (2007) 7
31. Bohlius J., Wilson J., Seidenfeld J., et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3 (2006) CD003407